Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$171.10
-0.9%		$162.92
$153.41
▼
$212.71
$265.24B0.272.81 million shs1.74 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.61
-1.2%		$49.56
$42.85
▼
$61.69
$102.32B0.334.49 million shs1.96 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.93
-1.6%		$146.79
$82.01
▼
$156.92
$357.33B0.2110.64 million shs3.92 million shs
Novartis AG stock logo
NVS
Novartis
$150.96
-3.4%		$148.31
$121.57
▼
$170.46
$286.96B0.411.98 million shs2.77 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+2.46%+3.59%+2.59%+2.35%+3.46%
GSK PLC Sponsored ADR stock logo
GSK
GSK
+2.18%+4.33%+0.95%-0.39%+15.76%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.72%+1.20%-2.39%+12.47%+68.27%
Novartis AG stock logo
NVS
Novartis
+1.44%+3.93%+10.65%+0.90%+18.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$171.10
-0.9%		$162.92
$153.41
▼
$212.71
$265.24B0.272.81 million shs1.74 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.61
-1.2%		$49.56
$42.85
▼
$61.69
$102.32B0.334.49 million shs1.96 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.93
-1.6%		$146.79
$82.01
▼
$156.92
$357.33B0.2110.64 million shs3.92 million shs
Novartis AG stock logo
NVS
Novartis
$150.96
-3.4%		$148.31
$121.57
▼
$170.46
$286.96B0.411.98 million shs2.77 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+2.46%+3.59%+2.59%+2.35%+3.46%
GSK PLC Sponsored ADR stock logo
GSK
GSK
+2.18%+4.33%+0.95%-0.39%+15.76%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.72%+1.20%-2.39%+12.47%+68.27%
Novartis AG stock logo
NVS
Novartis
+1.44%+3.93%+10.65%+0.90%+18.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.79
Moderate Buy$206.6720.79% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.05
Hold$55.339.33% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$151.924.83% Upside
Novartis AG stock logo
NVS
Novartis
2.20
Hold$145.60-3.55% Downside

Current Analyst Ratings Breakdown

Latest GSK, MRK, NVS, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/22/2026
Novartis AG stock logo
NVS
Novartis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy (B)
10/19/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
10/13/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Nordea Equity Research logo
Nordea Equity Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell ➝ Buy
10/13/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
10/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$125.00 ➝ $145.00
10/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetSector Perform$150.00 ➝ $145.00
10/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$70.00
10/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$120.00 ➝ $145.00
10/7/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$179.00 ➝ $177.00
10/6/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/6/2026
Novartis AG stock logo
NVS
Novartis
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$156.00
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.52$13.13 per share13.03$31.41 per share5.45
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.38$6.08 per share8.33$10.32 per share4.90
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.50$11.05 per share13.12$21.22 per share6.83
Novartis AG stock logo
NVS
Novartis
$54.53B5.28$10.53 per share14.33$22.04 per share6.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6925.5616.231.4217.02%31.45%13.20%10/30/2026 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.2015.8210.122.2514.56%43.23%11.60%10/28/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25115.8715.636.924.77%16.73%6.13%10/29/2026 (Estimated)
Novartis AG stock logo
NVS
Novartis
$13.98B$6.6322.6815.392.7923.29%38.56%14.47%10/27/2026 (Estimated)

Latest GSK, MRK, NVS, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.59N/AN/AN/A$16.02 billionN/A
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09N/AN/AN/A$17.31 billionN/A
10/28/2026Q3 2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.33N/AN/AN/A$11.76 billionN/A
10/27/2026Q3 2026
Novartis AG stock logo
NVS
Novartis
$2.25N/AN/AN/A$14.55 billionN/A
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
7/28/2026Q2 2026 & Strategy update
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.27$1.36+$0.09$0.28$11.02 billion$11.14 billion
7/27/2026Q2 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.50$2.63+$0.13$1.61$15.44 billion$15.38 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.54%+2.30%64.87%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.773.50%-7.86%55.31%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.35%+5.75%272.00%14 Years
Novartis AG stock logo
NVS
Novartis
$3.082.04%+5.28%46.46%N/A

Latest GSK, MRK, NVS, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45153.65%8/14/20268/14/202610/8/2026
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.36%9/15/20269/15/202610/7/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.47
0.89
0.67
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.81
0.82
0.52
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Novartis AG stock logo
NVS
Novartis
0.89
0.86
0.67

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable

Recent News About These Companies

Novartis Slides as Investors Appear to Lock In Gains Ahead of Q3 Results
 |  quiverquant.comQ
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
October 23 at 7:31 AM  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/novartis-breast-cancer-drug-cuts-risk-death-by-19-after-six-years-data-shows-2026-10-23/
NBT Bank N.A. Purchases 26,937 Shares of Novartis AG $NVS
October 23 at 6:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nbt-bank-na-purchases-26937-shares-of-novartis-ag-nvs-2026-10-23/
Novartis AG $NVS Stock Sold by Investment House LLC
October 23 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-stock-sold-by-investment-house-llc-2026-10-23/
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
October 22 at 10:15 AM  |  zacks.comhttps://www.zacks.com/stock/news/3012588/stay-ahead-of-the-game-with-novartis-nvs-q3-earnings-wall-street-s-insights-on-key-metrics?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm_preview-3012588
Novartis wins EU approval for Cosentyx in rheumatic disease
October 22 at 8:16 AM  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Novartis+wins+EU+approval+for+Cosentyx+in+rheumatic+disease/27214913.html
Novartis (NVS) Grew Sales Again as Entresto Fell 50%, Can Remibrutinib Carry It?
October 22 at 8:16 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novartis-nvs-grew-sales-again-172950985.html
Novartis AG $NVS Stock Acquired by South Shore Capital Advisors
October 20 at 1:44 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-stock-acquired-by-south-shore-capital-advisors-2026-10-20/
Novartis (NVS) Expected to Release Earnings on Tuesday
October 20 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-novartis-nvs-expected-to-release-earnings-on-tuesday-2026-10-20/
Novartis Halts Phase 2 Study of Iptacopan in Lupus Nephritis
October 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novartis-halts-phase-2-study-161252599.html
Novartis: The Sell-Off Creates An Attractive Entry Point
October 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4955199-novartis-the-sell-off-creates-an-attractive-entry-point
Novartis discontinues mid-stage Fabhalta trial in lupus nephritis for strategic reasons
October 19, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/novartis-discontinues-mid-stage-fabhalta-trial-in-lupus-nephritis-for-strategic-reasons/ar-AA2fzqvH
Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much?
October 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novartis-five-fast-growing-drugs-134500518.html
Novartis AG $NVS Stock Bought by TD Waterhouse Canada Inc.
October 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-stock-bought-by-td-waterhouse-canada-inc-2026-10-19/
Novartis discontinues mid-stage lupus trial in latest pipeline setback
October 16, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/novartis-discontinues-mid-stage-lupus-trial-in-latest-pipeline-setback/ar-AA2epCnC
Novartis' Loss of Exclusivity Continued to Erode Entresto Sales in Q3, RBC Says
October 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novartis-apos-loss-exclusivity-continued-150120173.html
Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis
October 16, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/novartis-halts-mid-stage-trial-for-kidney-drug-fabhalta-in-lupus-nephritis/ar-AA2eoFpR
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
October 16, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/novartis-ends-mid-stage-fabhalta-trial-targeting-serious-kidney-condition-2026-10-16/
12,480 Novartis AG $NVS Shares Sold by Triasima Portfolio Management inc.
October 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-12480-novartis-ag-nvs-shares-sold-by-triasima-portfolio-management-inc-2026-10-16/
Why Novartis (NVS) Stock Is Up Today
October 14, 2026  |  quiverquant.comQ
Novartis FY2027 Earnings Forecast Cut by Erste Group Bank
October 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-novartis-fy2027-earnings-forecast-cut-by-erste-group-bank-2026-10-14/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated Nike swoosh logo on a wall above a display pedestal with sneakers in a retail store.
Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
By Thomas Hughes | October 4, 2026
Kalshi and Polymarket logos beside a smartphone showing a prediction market on the Chiefs winning the Super Bowl, with a football in the background.
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
By Jessica Mitacek | October 8, 2026
Close-up of an Nvidia logo on a computer chip mounted on a circuit board with cables and hardware components.
NVIDIA Just Strengthened the Case for Its Massive Stock Price Upside
By Thomas Hughes | September 29, 2026
Television displaying the Netflix logo in a dark living room with a coffee table, popcorn bowl, and remote.
Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
By Sam Quirke | September 30, 2026
Laboratory workbench with chromatography instrument, pipettes, sample vials, and a notebook, with a production line visible beyond the glass wall.
3 Healthcare Dividend Stocks Offering More Than Just Income
By Chris Markoch | September 30, 2026
Astrazeneca stock logo

Astrazeneca NYSE:AZN

$171.10 -1.47 (-0.85%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK stock logo

GSK NYSE:GSK

$50.61 -0.60 (-1.17%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$144.93 -2.31 (-1.57%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis stock logo

Novartis NYSE:NVS

$150.96 -5.31 (-3.40%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas